Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors
Adrien Borgel, Etienne Camenen, Catherine Miquel, Philippe Bertheau, Luis Teixeira, Jacqueline Lehmann-Che · 2025
Read Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors by Adrien Borgel, Etienne Camenen, Catherine Miquel, Philippe Bertheau, Luis Teixeira, Jacqueline Lehmann-Che (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12853821.txt.
Description
Adrien Borgel and colleagues show two breast cancer subtype labels describe largely the same tumours. Their study from twenty twenty-five covers estrogen receptor negative cancers. Both subtypes are defined by androgen signalling activity. Different classifier systems, though, drew the groups separately.
Public and hospital datasets were classified both ways for comparison. Overlap between the two groups proved substantial. Shared tumours switched on androgen and growth pathways together. Tumours matching only one label carried more immune signals. A four-gene signature captured the overlapping group well. The test worked on fresh and preserved samples alike. Clearer subtype borders should improve trial design and treatment choice.
Catalog record
| CREATOR | Adrien Borgel, Etienne Camenen, Catherine Miquel, Philippe Bertheau, Luis Teixeira, Jacqueline Lehmann-Che |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |